North America Methotrexate Injection Market, By Product (Without Preservatives, With Preservatives), Type (Injectable Solution, Self-Injectable Solution), Availability (25mg/ml, 50mg/2ml), Dosage Form (Solution, Powder) Application (Cancer, Autoimmune Diseases, Pregnancy), Age Group (Adults, Geriatric, Pediatrics), Route of Administration (Intramuscular, Intravenous, Intra-Arterial, Intrathecal), End User (Hospitals, Clinics, Home Healthcare, Others) Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) Industry Trends and Forecast to 2029.
Market Definition and Insights
Methotrexate injection is employed alone or with other medicines to treat various types of cancer, such as breast, head and neck, lung, blood, bone, lymph node, and uterus cancers.
The high prevalence of autoimmune diseases, rise in the number of patients with inflammatory diseases, and rising healthcare expenditure is expected to drive the growth of the North America methotrexate injection market. However, the presence of alternatives for cancer treatment is expected to act as a restraining factor for market growth.
Methotrexate is a cancer therapy that prevents cancer cells from replicating. This helps to keep them from multiplying and spreading throughout your body. It may take up to 12 weeks after your methotrexate dose has been adjusted to the full level before you experience any benefits. The rising burden of autoimmune diseases and growing healthcare expenditure have accelerated the need for methotrexate injection, propelling the market's growth.
However, side effects and complications with the use of methotrexate hamper the growth of the North America Methotrexate Injection market in the forecast period.
North America methotrexate injection market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that North America North America methotrexate injection market will grow at a CAGR of 6.0% during the forecast period of 2022 to 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Product (Without Preservatives, With Preservatives), Type (Injectable Solution, Self-Injectable Solution), Availability (25mg/ml, 50mg/2ml), Dosage Form (Solution, Powder) Application (Cancer, Autoimmune Diseases, Pregnancy), Age Group (Adults, Geriatric, Pediatrics) Route Of Administration (Intramuscular, Intravenous, Intra-Arterial, Intrathecal), End User (Hospitals, Clinics, Home Healthcare, Others) Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico
|
|
Market Players Covered
|
Pfizer Inc., Antares Pharma, Inc., Fresenius Kabi USA, Medexus Pharmaceuticals, Inc., Viatris Inc. , Sandoz AG (A Subsidiary of Novartis AG), Teva Pharmaceuticals USA, Inc., Accord BioPharma, Hikma Pharmaceuticals PLC, Cumberland Pharmaceuticals Inc., PV Pharma among others.
|
Methotrexate Injection Market Dynamics
Drivers
- Increased prevalence of cancer
The increasing patient population with breast cancer, lung cancer, head and neck cancer, and blood cancer is fuelling the growth of North America methotrexate injection market. Breast cancer is the most recurrent invasive cancer in women, and it is the second leading cause of death in women after lung cancer. The American Cancer Society estimates that 41,760 women have breast cancer. Breast cancer starts quite small, to be felt. As the growth continues, the tumor spreads to the breast and other parts of the body. It results in serious health issues and can cause death. 80% of lung cancer deaths are caused due to smoking and exposure to tobacco. Lung cancer exists as the leading cause of death, with an estimated 1.8 million deaths.
- Government initiatives to spread awareness about lung and breast cancer
Government initiatives refer to statements or programs which are necessitated to solve the problem. The government raises awareness or delivers better health and safety initiatives to treat breast cancer in women and lung cancer. It promotes partnerships among healthcare organizations, facilities and manufacturers to necessitate the therapy and treatment for breast cancer in women and lung cancer.
The initiatives conducted by the government will result in the safety of the patient, cost savings, and less surgical care impact. In addition, hospitals and healthcare organizations will profit by enforcing protocols by collaborating with government organizations for supply and delivery. The government has already started funding such work in a small way but believes that more needs to be done. Therefore, this feature is expected to supplement the growth of the North America methotrexate injection market.
Opportunity
- Strategic initiatives by the market players
An increase in the burden of various types of cancers and thyroid nodules malignancy across the regions and the increase in the geriatric population has created more demand for diagnostic procedures for the timely treatment of patients. The main aim is to improve health management and diagnostics for quality performance before reaching the critical stages of the disease. Major market players focus on filling the demands of healthcare professionals and spending a quite noticeable amount for better products.
Major players are involved in making the strategies and implementing them, such as acquisition, and product launch.
Restraints/Challenges
Research and development are prerequisites for modifying the products of advanced nature. As the demand for diagnostic procedures for cancer increases, companies are investing more in research and development to offer the best diagnostic options for convenient patient outcomes.
Research laboratories are lately investing more in products and procedures due to rising cases of cancer and its requirement of early diagnosis to save the patient's life. Research and development have enhanced customization in diagnosis since all humans' cells and tissues are not the same.
The increasing tobacco consumption and the rising growing population have surged cancer cases globally. Thereby the demand for research and development in pharmaceutical industries for diagnosis of it is also getting hyped. Hence increasing research and development activities are anticipated to be a greater opportunity for North America methotrexate injection market.
Furthermore, the use of methotrexate across the globe is rapidly increasing, with the growth of the aged population and several carcinogenic diseases which are preventable by the early diagnosis. At the same time, the players of the methotrexate injection manufacturers in the market have to follow certain regulations to get approval from the upper authorities to launch the product in the market. These stringent guidelines need to be followed, and this is one of the most difficult tasks among all the steps. The pre-market approval of various medical devices varies from one country to another. The Food and Drug Administration (FDA) regulate the U.S.
North America methotrexate injection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on North America methotrexate injection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In March 2022, Viatris Inc. and Kindeva Drug Delivery L.P. announced that Mylan Pharmaceuticals Inc., a Viatris subsidiary, had received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Breyna (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), the first approved generic version of AstraZeneca's Symbicort.
- In January 2022, Cumberland Pharmaceuticals Inc., a speciality pharmaceutical company, entered into and closed on a definitive agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO from Kyowa Kirin, Inc. the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. a global speciality pharmaceutical company focused on discovering and delivering novel medicines. This has helped the company to expand its business.
North America Methotrexate Injection Market
North America Methotrexate Injection market is categorized into nine notable segments based on product, type, availability, dosage form, application, age group, route of administration, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- By Product
- With Preservatives
- Preservative Free
Based on product, the North America methotrexate injection market is segmented into with preservatives and preservatives free.
- By Type
- Self-Injectable Solution
- Injectable Iv Solution
Based on type, the North America methotrexate injection market is segmented into with self-injectable solution and injectable IV solution
- Availability
- 25mg/ml
- 50mg/2ml
Based on availability, the North America methotrexate injection market is segmented into 25MG/ML and 50MG/2ML
- Dosage Form
- Solution
- Powder
Based on dosage, the North America methotrexate injection market is segmented into solution and powder
- Application
- Cancer
- Autoimmune Diseases
- Pregnancy
Based on application, the North America methotrexate injection market is segmented into cancer, autoimmune diseases, pregnancy.
- Age Group
- Pediatrics
- Adults
- Geriatric
Based on age group, the North America methotrexate injection market is segmented into pediatrics, adults and geriatrics
- Route of Administration
- Intramuscular
- Intravenous
- Intra-Arterial
- Intrathecal
Based on route of administration, the North America methotrexate injection market is segmented into intramuscular, intravenous, intra-arterial, intrathecal
- End User
- Hospitals
- Clinics
- Home Healthcare
- Others
Based on end user, the North America methotrexate injection market is segmented into hospitals, clinics, home healthcare and others
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacy
- Online Pharmacy
- Others
Based on distribution channel, the North America methotrexate injection market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.
North America Methotrexate Injection Market Regional Analysis/Insights
The North America methotrexate injection market is analyzed and market size insights and trends are provided by country, product, type, availability, dosage form, application, age group, route of administration, distribution channel and end-user as referenced above.
The countries covered in the North America methotrexate injection market report are the U.S., Canada and Mexico.
The U.S. dominates the North America methotrexate injection market because of the presence of a large number of manufacturers, rise in government initiatives and organizations within the region.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Methotrexate Injection Market Share Analysis
North America methotrexate injection market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on methotrexate injection market.
Some of the major players in the market are Pfizer Inc., Antares Pharma, Inc., Fresenius Kabi USA, Medexus Pharmaceuticals, Inc., Viatris Inc., Sandoz AG (A Subsidiary of Novartis AG), Teva Pharmaceuticals USA, Inc., Accord BioPharma, Hikma Pharmaceuticals PLC, Cumberland Pharmaceuticals Inc., PV Pharma among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global Vs Regional and Vendor Share Analysis. Please request an analyst call in case of further inquiry.
SKU-